title: Serotonin, locomotion, exploration, and place recall in the rat.
abstract: Intracerebroventricular injection of 5,7-dihydroxytryptamine (5,7-DHT) led to a 90% reduction of the 5-hydroxytryptamine (5-HT) reuptake site. Behavioural symptoms were studied early (45 to 93 h) as well as late (11 to 14 days) in the postoperative period. Forty-five hours postoperatively, recall of a place navigation task in a water maze was clearly impaired in 5,7-DHT-treated animals. This impairment had disappeared by the fifth postoperative session. During the early test period, injection of scopolamine (0.5 mg/kg) or d-amphetamine (3.0 mg/kg) did not affect place recall of the vehicle-treated control group. In contrast, 5,7-DHT-treated animals were impaired by administration of scopolamine, but not d-amphetamine. During the late test period, the place recall of both groups was affected by scopolamine, but only the performance of the 5,7-DHT lesioned animals was sensitive to d-amphetamine. Locomotion was not severely affected at any time after 5,7-DHT treatment. The vertical hole-board test indicated that the exploratory activities of the animals were relatively unaffected by 5,7-DHT when measured 48 h postoperatively. At 14 days postsurgery, the 5,7-DHT-treated animals demonstrated an impaired habituation of the exploratory behaviour.
authors.affiliation: Department of Psychology, University of Copenhagen, Amager, Njalsgade 88, DK-2300 Copenhagen S, Denmark. jesper.mogensen@psy.ku.dk
authors.forename: Jesper
authors.initials: J
authors.lastname: Mogensen
authors.forename: Gitta
authors.initials: G
authors.lastname: Wörtwein
authors.forename: Per
authors.initials: P
authors.lastname: Plenge
authors.forename: Erling T
authors.initials: ET
authors.lastname: Mellerup
mesh_terms: D015116:5,7-Dihydroxytryptamine / Q000494:pharmacology; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects / Q000502:physiology; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D005106:Exploratory Behavior / Q000502:physiology*; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D011939:Mental Recall / Q000502:physiology*; D009043:Motor Activity / Q000502:physiology*; D018727:Muscarinic Antagonists / Q000494:pharmacology; D050484:Norepinephrine Plasma Membrane Transport Proteins; D051381:Rats; D017208:Rats, Wistar; D044282:Receptor, Serotonin, 5-HT1A / Q000187:drug effects; D044302:Receptor, Serotonin, 5-HT1B / Q000187:drug effects; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D012601:Scopolamine / Q000494:pharmacology; D012701:Serotonin / Q000502:physiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D027981:Symporters / Q000378:metabolism
chemical_list: D015116:5,7-Dihydroxytryptamine; D000661:Amphetamine; D000697:Central Nervous System Stimulants; D018727:Muscarinic Antagonists; D050484:Norepinephrine Plasma Membrane Transport Proteins; D044282:Receptor, Serotonin, 5-HT1A; D044302:Receptor, Serotonin, 5-HT1B; D044402:Receptor, Serotonin, 5-HT2A; D011943:Receptors, Adrenergic, beta; D012601:Scopolamine; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D027981:Symporters; C493226:Slc6a2 protein, rat